Kinetics of Bilirubin and Ammonia Elimination during Hemadsorption Therapy in Secondary Sclerosing Cholangitis Following ECMO Therapy and Severe COVID-19
Open Access
- 5 December 2021
- journal article
- case report
- Published by MDPI AG in Biomedicines
- Vol. 9 (12) , 1841
Abstract
In critically ill patients, liver dysfunction often results in coagulopathy and encephalopathy and is associated with high mortality. Extracorporeal clearance of hepatotoxic metabolites, including bilirubin and ammonia, aims to attenuate further hepatocyte damage and liver injury, resulting in decreased mortality. The efficacy of hemadsorption combined with conventional hemodialysis to eliminate bilirubin and ammonia to support the liver’s excretory function in acute liver injury has been described previously. However, the optimal use of liver support systems in chronic liver dysfunction due to secondary sclerosing cholangitis in critically ill patients (SSC-CIP) has not been defined yet. We herein describe the kinetics of successful bilirubin and ammonia elimination by hemadsorption in a patient with SSC-CIP after extracorporeal membrane oxygenation (ECMO) therapy for severe acute respiratory distress syndrome (ARDS) in a patient with coronavirus disease 2019 (COVID-19). During the course of the disease, the patient developed laboratory signs of liver injury during ECMO therapy before clinically detectable jaundice or elevated bilirubin levels. A diagnosis of SSC-CIP was confirmed by endoscopic retrograde cholangiopancreatography (ERCP) based on intraductal filling defects in the intrahepatic bile ducts due to biliary casts. The patient showed stable elevations of bilirubin and ammonia levels thereafter, but presented with progressive nausea, vomiting, weakness, and exhaustion. Based on these laboratory findings, hemadsorption was combined with hemodialysis treatment and successfully eliminated bilirubin and ammonia. Moreover, direct comparison revealed that ammonia is more efficiently eliminated by hemadsorption than bilirubin levels. Clinical symptoms of nausea, vomiting, weakness, and exhaustion improved. In summary, bilirubin and ammonia were successfully eliminated by hemadsorption combined with hemodialysis treatment in SSC-CIP following ECMO therapy and severe COVID-19. This observation is particularly relevant since it has been reported that a considerable subset of critically ill patients with COVID-19 suffer from liver dysfunction associated with high mortality.Keywords
This publication has 60 references indexed in Scilit:
- Acute liver failure: A curable disease by 2024?Journal of Hepatology, 2015
- Acute Liver FailureNew England Journal of Medicine, 2013
- Purification methods: a way to treat severe acute inflammation related to sepsis?Critical Care, 2013
- Ammonia clearance with haemofiltration in adults with liver diseaseLiver International, 2013
- Hypoxic liver injury and cholestasis in critically ill patientsCurrent Opinion in Critical Care, 2013
- Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsisKidney International, 2012
- Hepatic encephalopathy: Suspect it early in patients with cirrhosisCleveland Clinic Journal of Medicine, 2011
- Effects of hemoadsorption on cytokine removal and short-term survival in septic ratsCritical Care Medicine, 2008
- Incidence and prognosis of early hepatic dysfunction in critically ill patients—A prospective multicenter studyCritical Care Medicine, 2007
- Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-κB DNA binding, and improves short-term survival in lethal endotoxemia*Critical Care Medicine, 2004